A Phase 3 interventional study of Mirvetuximab soravtansine and Paclitaxel in Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma and Fallopian Tube Cancer, sponsored by ImmunoGen, Inc.. Completed at 131 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.
Sponsored by ImmunoGen, Inc. (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial — 2 open to participants now, 3 under way, 1 of them phase 3. Paclitaxel · Carcinoma, Ovarian Epithelial.
Among the 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial, this one is the 12th largest by enrollment of the 60 interventional ones that give a count, is the only one that started in 2016, is one of 17 in phase 3, and was the 65th registered.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
Browse Carcinoma, Ovarian Epithelial studies →2 of the 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial are open now, in 2 countries. Recruiting first, the newest first:
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–75 · Women only
Massachusetts General Hospital · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 31 · Phase 3 19
First in 1994; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Median enrollment 47 across the 60 interventional studies. Of the 56 that completed or were terminated, 11 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 71 have an industry lead sponsor. The 10 most frequent:
This study is registered under ImmunoGen, Inc., one of the names counted as AbbVie. Under that name alone:
ImmunoGen, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
AbbVie has 6 studies filed under Carcinoma, Ovarian Epithelial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 71 studies testing paclitaxel in Carcinoma, Ovarian Epithelial, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee \[BIRC\]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
Drug: Mirvetuximab soravtansine
Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
Drug: Paclitaxel · Drug: Pegylated liposomal doxorubicin · Drug: Topotecan
Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
Paclitaxel will be administered per dose and schedule specified in the arm.
Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Topotecan will be administered per dose and schedule specified in the arm.
Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study
PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)
PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by BIRC Per RECIST1.1
ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the SoD of target lesions, taking as reference the baseline SoD.
Time frame: From randomization until first BOR of CR or PR (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death from any cause. Participants who did not experience the event of death were censored at their last date known to be alive. OS was estimated using the Kaplan-Meier method.
Time frame: From the date of randomization until the time of death (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Number of Participants Achieving at Least a 15% (≥ 15-Point) Absolute Improvement From Baseline on the EORTC QLQ-OV28 Abdominal/Gastrointestinal (AB/GI) Symptom Subscale at Week 8/9 Assessment
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer 28 (EORTC QLQ-OV28) is a 28-item ovarian cancer supplemental module. It comprises of 6 symptom scales (AB/GI symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal symptoms, body image, attitude to disease, treatment), and sexual functioning. Participants were asked to indicate extent to which they experienced AB/GI symptoms. Participants responded on a scale of 1-4(1=not at all, 2=a little, 3=quite a bit, 4=very much) to following: Did you have abdominal pain? Did you have a bloated feeling in your abdomen? Did you have problems with your clothes feeling too tight? Did you experience any change in bowel habit as a result of your disease or treatment? Were you troubled by passing wind/gas/flatulence? Have you felt full too quickly after beginning to eat? Have you had indigestion/heartburn? Data were transformed to a scale from 0-100. Lower scores=better health.
Time frame: Baseline, Week 8/9
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Adverse event (AE): any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity: graded per National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Relation of AE to treatment was determined by investigator. Serious AEs: death, life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent/significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs: any AE that emerged on or after the first dose, and within 30 days of the last dose. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported AEs module.
Time frame: From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Gynecologic Cancer Intergroup (GCIG) CA-125 Response Rate: Percentage of Participants With GCIG CA-125 Confirmed Clinical Responses
CA-125 Response rate wasdefined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100.
Time frame: From first dose of study drug until CA-125 response (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
PFS, as Assessed by Investigator Per RECIST Version 1.1
PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Duration of Response (DOR), as Assessed by BIRC Per RECIST v1.1
DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of PD. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.
Time frame: From the date of first response (CR or PR) until the date of PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-methyl DM4
PK parameters were calculated using standard non-compartmental methods.
Time frame: Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1 and 3; and Day 8 and 15 of Cycles 1 and 3
Number of Participants With Anti-Drug Antibodies (ADA)
An electrochemiluminescent method was used for the detection of anti-mirvetuximab soravtansine antibodies in plasma from samples collected in dipotassium ethylenediaminetetraacetic acid (K2EDTA) tubes. The qualitative assay was designed to detect anti-mirvetuximab soravtansine antibodies in human plasma.
Time frame: Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1, 2, and 4; pre-dose on Day 1 of Cycle 6
| Milestone | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Started | 248 | 118 |
| Safety population | 243 | 109 |
| Completed | 129 | 55 |
| Not completed | 119 | 63 |
| Withdrew: Death | 96 | 50 |
| Withdrew: Investigator's discretion | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 16 | 9 |
| Withdrew: Other than specified | 4 | 4 |
PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
| months | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study | 4.14 (3.75 to 4.53) | 4.44 (2.83 to 5.59) |
PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
| months | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining) | 4.76 (4.11 to 5.68) | 3.25 (1.97 to 5.59) |
ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the SoD of target lesions, taking as reference the baseline SoD.
| percentage of participants | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by BIRC Per RECIST1.1 | 22 (17.2 to 27.9) | 12 (6.6 to 19.1) |
OS was defined as the time from the date of randomization until the date of death from any cause. Participants who did not experience the event of death were censored at their last date known to be alive. OS was estimated using the Kaplan-Meier method.
| months | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 15.57 (12.85 to 18.04) | 13.93 (11.40 to 18.50) |
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer 28 (EORTC QLQ-OV28) is a 28-item ovarian cancer supplemental module. It comprises of 6 symptom scales (AB/GI symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal symptoms, body image, attitude to disease, treatment), and sexual functioning. Participants were asked to indicate extent to which they experienced AB/GI symptoms. Participants responded on a scale of 1-4(1=not at all, 2=a little, 3=quite a bit, 4=very much) to following: Did you have abdominal pain? Did you have a bloated feeling in your abdomen? Did you have problems with your clothes feeling too tight? Did you experience any change in bowel habit as a result of your disease or treatment? Were you troubled by passing wind/gas/flatulence? Have you felt full too quickly after beginning to eat? Have you had indigestion/heartburn? Data were transformed to a scale from 0-100. Lower scores=better health.
| Participants | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants Achieving at Least a 15% (≥ 15-Point) Absolute Improvement From Baseline on the EORTC QLQ-OV28 Abdominal/Gastrointestinal (AB/GI) Symptom Subscale at Week 8/9 Assessment | 45 | 7 |
Adverse event (AE): any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity: graded per National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Relation of AE to treatment was determined by investigator. Serious AEs: death, life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent/significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs: any AE that emerged on or after the first dose, and within 30 days of the last dose. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported AEs module.
| Participants | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 242 | 107 |
CA-125 Response rate wasdefined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100.
| percentage of participants | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Gynecologic Cancer Intergroup (GCIG) CA-125 Response Rate: Percentage of Participants With GCIG CA-125 Confirmed Clinical Responses | 51 (44.1 to 58.3) | 27 (17.6 to 37.8) |
PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
| months | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| PFS, as Assessed by Investigator Per RECIST Version 1.1 | 4.27 (4.11 to 5.06) | 4.24 (2.76 to 5.36) |
DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of PD. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.
| months | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Duration of Response (DOR), as Assessed by BIRC Per RECIST v1.1 | 5.65 (4.17 to 8.51) | 7.26 (4.14 to NA) |
PK parameters were calculated using standard non-compartmental methods.
| hours*milligrams/milliliter (hr*mg/mL) | Mirvetuximab Soravtansine |
|---|---|
| Mirvetuximab Soravtansine at Cycle 1 | 20.53 ± 10.31 |
| Mirvetuximab Soravtansine at Cycle 3 | 22.40 ± 7.770 |
| Total M9346A antibody at Cycle 1 | 23.23 ± 9.463 |
| Total M9346A antibody at Cycle 3 | 31.20 ± 11.52 |
| DM4 at Cycle 1 | 348.5 ± 265.7 |
| DM4 at Cycle 3 | 347.4 ± 280.9 |
| S-methyl DM4 at Cycle 1 | 1586 ± 1496 |
| S-methyl DM4 at Cycle 3 | 1512 ± 1278 |
An electrochemiluminescent method was used for the detection of anti-mirvetuximab soravtansine antibodies in plasma from samples collected in dipotassium ethylenediaminetetraacetic acid (K2EDTA) tubes. The qualitative assay was designed to detect anti-mirvetuximab soravtansine antibodies in human plasma.
| Participants | Mirvetuximab Soravtansine |
|---|---|
| Number of Participants With Anti-Drug Antibodies (ADA) | 13 |
Collected over From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mirvetuximab Soravtansine | 96/243 (39.5%) | 67/243 (27.6%) | 242/243 (99.6%) |
| Investigator's Choice (IC) Chemotherapy | 50/109 (45.9%) | 31/109 (28.4%) | 106/109 (97.2%) |
| Event | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 10/243 | 3/109 |
| Small intestinal obstructionGastrointestinal disorders | 5/243 | 4/109 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 7/243 | 2/109 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 5/243 | 3/109 |
| SepsisInfections and infestations | 3/243 | 3/109 |
| PyrexiaGeneral disorders | 0/243 | 3/109 |
| Large intestinal obstructionGastrointestinal disorders | 4/243 | 2/109 |
| Abdominal painGastrointestinal disorders | 2/243 | 2/109 |
| VomitingGastrointestinal disorders | 2/243 | 2/109 |
| AscitesGastrointestinal disorders | 1/243 | 2/109 |
| Event | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| NauseaGastrointestinal disorders | 131/243 | 46/109 |
| DiarrhoeaGastrointestinal disorders | 107/243 | 18/109 |
| Vision blurredEye disorders | 104/243 | 6/109 |
| NeutropeniaBlood and lymphatic system disorders | 16/243 | 43/109 |
| FatigueGeneral disorders | 83/243 | 38/109 |
| Abdominal painGastrointestinal disorders | 80/243 | 23/109 |
| KeratopathyEye disorders | 77/243 | 1/109 |
| AnaemiaBlood and lymphatic system disorders | 34/243 | 32/109 |
| ConstipationGastrointestinal disorders | 64/243 | 31/109 |
| Dry eyeEye disorders | 68/243 | 2/109 |
ITT population included all participants randomized in the study.
| Age, Continuous(years) | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Mean | 62.7 ± 10.29 | 62.9 ± 10.51 | 62.8 ± 10.35 |
| Sex: Female, Male(Participants) | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Female | 248 | 118 | 366 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 9 | 21 |
| Not Hispanic or Latino | 225 | 102 | 327 |
| Unknown or Not Reported | 11 | 7 | 18 |
| Race (NIH/OMB)(Participants) | Mirvetuximab Soravtansine | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 6 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 3 | 10 |
| White | 225 | 105 | 330 |
| More than one race | 2 | 2 | 4 |
| Unknown or Not Reported | 8 | 5 | 13 |
Showing the first 100 of 131 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Jan 2019, 34 months.
Results were first posted in Jun 2020, 1 year 5 months after primary completion.
Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mirvetuximab soravtansine · Paclitaxel · Liposomal doxorubicin · Topotecan
Carcinoma, Ovarian Epithelial →